MRK drops Preladenant program in Parkinson’s disease after phase-3 failure: http://finance.yahoo.com/news/merck-provides-phase-iii-clinical-210000918.html Fortunately, this was not one of the big-4 opportunities in MRK’s pipeline, which are enumerated in #msg-88122327.